Atea Pharmaceuticals, Inc. SEC Filings

Form 4 filing (24-Jun-2025) reveals that Atea Pharmaceuticals (AVIR) director Franklin M. Berger increased his ownership through equity-based compensation granted on 20-Jun-2025. A total of 29,600 previously issued restricted stock units (RSUs) vested and converted into common shares (Code M) at a $0.00 cost, lifting his direct holdings to 506,497 shares. Concurrently, Berger received 29,600 new RSUs that will vest at the next annual meeting or one-year anniversary, and 41,200 stock options with a $3.25 exercise price expiring 19-Jun-2035, vesting monthly over 12 months. No shares were sold. The transactions signal net insider accumulation while introducing modest potential dilution through the new RSUs and options.

Form 4 highlights for Atea Pharmaceuticals, Inc. (AVIR)

• Reporting person: Bruce Polsky, Director.
• Transaction date: 20 Jun 2025; filing date 24 Jun 2025.
• Non-derivative shares: 29,600 common shares acquired at $0.00 upon RSU vesting; total direct ownership now 95,206 shares.
• New derivative grants:
  • 29,600 Restricted Stock Units (RSUs) that vest on the earlier of the 2026 annual meeting or 1-year anniversary of grant.
  • 41,200 stock options with a $3.25 exercise price, vesting monthly over 12 months and expiring 19 Jun 2035.
• Derivative disposition: 29,600 RSUs converted to common stock (code “M”), leaving zero balance for that award.

The filing reflects routine director equity compensation—no open-market buying or selling—and increases Mr. Polsky’s direct equity stake in AVIR. No cash outlay was required for the RSU conversion; the new option strike establishes the cost basis for potential future purchases.

Form 4 highlights for Atea Pharmaceuticals (AVIR): Director Jerome M. Adams reported several equity transactions on 20 June 2025.

• Common shares acquired: 29,600 shares were received upon conversion of previously vested restricted stock units (RSUs) at an effective price of $0.00 (code M). Adams now holds 62,750 AVIR shares directly.
• New equity awards granted:
• RSUs: 29,600 units granted (code A). They vest in a single installment on the earlier of the next annual meeting or the first anniversary of grant, subject to continued service.
• Stock options: 41,200 options granted with a $3.25 exercise price, expiring 19 June 2035. Vest monthly over 12 months, fully vested after one year.
• No derivative securities were sold; 29,600 RSUs were converted and the related derivative position is now zero.

Overall, the director increased his direct equity stake and received additional incentive-based awards, signaling continued alignment with shareholder interests.

Atea Pharmaceuticals (AVIR) filed a Form 4 on 24 Jun 2025 for director Bruno Lucidi covering transactions dated 20 Jun 2025.

• Common stock acquired: 29,600 shares were issued upon the full vesting and conversion of previously granted restricted stock units (RSUs) at a cost of $0, raising Lucidi’s direct holdings to 112,750 shares.
• New equity grants: (i) 29,600 RSUs that vest in a single tranche on the earlier of the next annual shareholder meeting or the first anniversary of grant; (ii) 41,200 stock options with a $3.25 exercise price, vesting in 12 equal monthly installments through 20 Jun 2026 and expiring on 19 Jun 2035.
• No open-market purchases or sales were reported; all activity reflects equity incentive awards and conversions.

The filing indicates continued insider equity ownership alignment, with a modest increase in direct share count and fresh long-term option incentives.